One reason for failure to cure solid tumors by surgery appears to be the impossibility of controlling metastases that are present but latent at the time of operation.
Malignant growth of cells is often characterized by disorganization of tissue structure, abnormal blood vessel development, and insuffi- cient vascular supply.
Predictive drug testing on human tumor cells in order to define the appropriate chemotherapy will remain imperative as long as the anticancer agents available are few in number and show only limited activity.
At first glance it appears that little has happened in our understanding of bronchogenic carcinoma, since five year survival rates have not changed appreciably over the past ten years.
This publication brings together a number of papers presented at the Fourth Symposium on Clinical Oncology held at the Royal College of Radiologists, London, in February 1982.
The enormous expansion seen over the last decade in the mammo- graphic detection of breast cancer lesions, especially the use of screen- ing procedures for the early detection of clinically unsuspected tumors, has made it necessary to summarize the experience made by various centers in the world.
Substantial relief of discomfort may be anticipated by most patients suffering from pelvic and lower-extremity pain who are treated by arterial infusion of nitrogen mustard.
rope it was mainly the states of the northern and centrat European areas which succeeded in achieving the extermi- nation or at least the regression of brucellosis.
Lactogenic hormone activity was first observed in bovine pituitary extracts by Stricker and Griiter in 1928, working in Bouin's laboratory in Strasbourg.
Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity.
Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10].
Several years ago a friendly looking young man walked into my office at the University Department of Dermatology in Cologne, introduced himself as a diplomate chemist, executive member of a family-owned, rather small German company manufacturing hair care products, and proposed to me straight forward to organize an international meeting on hair research.
